{"id":46104,"date":"2024-02-15T12:31:12","date_gmt":"2024-02-15T12:31:12","guid":{"rendered":"https:\/?p=46104"},"modified":"2024-02-15T12:31:12","modified_gmt":"2024-02-15T12:31:12","slug":"sage-therapeutics-faces-depression-drug-approval-delays","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/sage-therapeutics-faces-depression-drug-approval-delays\/","title":{"rendered":"SAGE Therapeutics Faces Depression Drug Approval Delays"},"content":{"rendered":"

SAGE Therapeutics Inc. (SAGE: NSD<\/a><\/strong>)<\/strong> has recently encountered unforeseen turbulence. A new risk has emerged and is adding pressure to the biotech firm’s stock value. Regulatory review delays over their depression drug, SAGE-217, have raised safety concerns, presenting a potential impact on SAGE Therapeutics’ stock price.<\/span><\/p>\n

 <\/p>\n

Stock Target Advisor’s Take on SAGE Therapeutics:<\/strong><\/h2>\n

Stock Target Advisor<\/strong><\/a> advises a ‘Strong Sell’ rating on SAGE Therapeutics stock, presenting a firm target price of 23.33. With a projected price change expected to fall by -9.39% over the next 12 months, it’s clear to see why the stock raises concerns. The average analyst target price for Sage Therapeutic stands at USD 24.64, a shade higher, with a collective average rating of ‘Buy’.<\/span><\/p>\n

The market offers a brighter perspective on SAGE Therapeutics, with seven covering analysts collectively advising a ‘Buy’ rating. The average price target stands at 24.64, with values ranging from a minimum target price of 18 to a maximum of 34.<\/span><\/p>\n

SAGE Therapeutics operates under the biotechnology sector<\/a><\/strong>, which currently receives an average analyst rating of ‘Strong Buy.’ Conversely, Stock Target Advisor leans bearish on this sector.\u00a0<\/span><\/p>\n

 <\/p>\n

SAGE Therapeutics: An Overview of Financial Performance\u00a0<\/strong><\/h2>\n

Over the past year, SAGE Therapeutics’ stock suffered a capital loss of -42.92%, ranking it on the 40.09th percentile on sectorial capital gains. No dividend returns were realized, generating a gross total return equal to the listed capital loss.<\/span><\/p>\n

<\/p>\n

\n
\n

SAGE Ratings<\/a> by Stock Target Advisor<\/p>\n<\/div>\n